Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients

Lourdes Martín-Martín; Sara Gutiérrez-Herrero; María Herrero-García; Alejandro Martín García-Sancho; Ana Yeguas; Ana-África Martín-López; Lucía López-Corral; Estefanía Pérez-López; Marta García-Blázquez; Fermín Sánchez-Guijo; María Belén Vidriales; Giuseppe Gaipa; INCAR consortium; EuroFlow consortium; Alberto Orfao

doi:10.1038/s41408-024-01065-z

Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients

Blood Cancer J. 2024 May 17;14(1):83. doi: 10.1038/s41408-024-01065-z.

Authors

Lourdes Martín-Martín^#^{1

2

3

4

5}, Sara Gutiérrez-Herrero^#^{1

2

3

4}, María Herrero-García^{1

2

3

4}, Alejandro Martín García-Sancho^{3

4

5

6}, Ana Yeguas^{3

4

6}, Ana-África Martín-López^{3

4

5

6}, Lucía López-Corral^{3

4

5

6}, Estefanía Pérez-López^{3

4

5

6}, Marta García-Blázquez⁶, Fermín Sánchez-Guijo^{3

4

5

6}, María Belén Vidriales^{3

4

5

6}, Giuseppe Gaipa⁷; INCAR consortium; EuroFlow consortium; Alberto Orfao^{8

9

10

11

12}

Collaborators

Alberto Orfao, María Belén Vidriales

Affiliations

¹ Translational and Clinical Research Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC), and University of Salamanca, Salamanca, Spain.
² Flow Cytometry Service (NUCLEUS), University of Salamanca, Salamanca, Spain.
³ Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
⁴ Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain.
⁵ Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Carlos III Health Institute, Madrid, Spain.
⁶ Department of Hematology, University Hospital of Salamanca, Salamanca, Spain.
⁷ Tettamanti Center and Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
⁸ Translational and Clinical Research Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC), and University of Salamanca, Salamanca, Spain. [email protected].
⁹ Flow Cytometry Service (NUCLEUS), University of Salamanca, Salamanca, Spain. [email protected].
¹⁰ Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. [email protected].
¹¹ Department of Medicine, University of Salamanca (Universidad de Salamanca), Salamanca, Spain. [email protected].
¹² Biomedical Research Networking Centre Consortium of Oncology (CIBERONC), Carlos III Health Institute, Madrid, Spain. [email protected].

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antigens, CD19* / immunology
Female
Humans
Immunotherapy, Adoptive* / methods
Lymphoma, Large B-Cell, Diffuse* / blood
Lymphoma, Large B-Cell, Diffuse* / immunology
Lymphoma, Large B-Cell, Diffuse* / therapy
Male
Middle Aged
Receptors, Chimeric Antigen / immunology
T-Lymphocytes / immunology
Treatment Outcome

Substances

CD19 molecule, human